About Us
------------------------------
Our Philosophy
------------------------------
Mission Statement
------------------------------

What is BT
------------------------------
How BT Works
------------------------------
Why BT Works

------------------------------
Will it Work for You
------------------------------
History of BT
------------------------------
Diseases Treated
------------------------------
Physical Science
------------------------------
Bibliography
------------------------------
Testimonials
------------------------------
Cancer Glossary
------------------------------
Links & Literature
------------------------------
Newsletter
------------------------------
Physicians
------------------------------
Contact Us
 
 

 
 

 
 
 
 

How BT Works


 
The Clinical Application

An Ultraviolet Blood session is similar to donating blood, where a small amount of blood is taken from a patient, exposed to ultraviolet light, and returned to the patient in a sanitary, “closed loop” system. It’s simple, painless and effective.

The Process

(Biophotonic Therapy) destroys “bad cells” and works by binding the DNA of any disease, virus or bacteria in the extracted blood. When blood is returned to the patient it does a number of positive things;

 
Number one, the exposed blood creates a secondary Biophotonic effect up to 3 days following a treatment whereby all of the treated blood binds to the DNA of all of the diseased cells, viruses and bacteria in the body.

Number two, the altered diseased cells, viruses and bacteria are recognized and “Marked” by the BT and the patient’s immune system then develops anti-bodies against the diseased cells, viruses and bacteria, thereby creating a natural vaccine.

Number three, allows the body to work at peak performance with less effort by balancing all the systems of the body. Only your own immune system cures diseases and Biophotonic Therapy works with your immune system to keep it healthy.

Biophotonic Therapy is Simple, Painless, and Effective and is done on an outpatient basis or in a clinic.


Mechanisms of Action

From the early years of BT therapy, Knott and his associates sought to explain how BT treatments work and of its therapeutic effects. They and subsequent researchers identified two possible modes:

The UV treatment of the blood in the treatment chamber destroys or alters bacteria and viruses in the extracted blood in such a way as to create a kind of vaccination effect when they return to the body. This provokes a reaction by the immune system which in turn destroys most or all of the other bacteria or virus in the body; and

The treatment of a small fraction (some 5 percent) of the blood then spreads throughout the entire volume of the blood upon returning to the body, and this induced secondary radiation (biophotons are emitted by the activated cells) destroys virus, bacteria, and in autoimmune diseases, activated white blood cells.

The lack of detailed understanding of immunology at the peak of the use of BT therapy in the United States in the 1940s kept researchers from determining which of these two effects is more powerful, and in which applications. It also obscured a possible third pathway: that the treatment itself, though quite modest in level, has an impact on the autonomic nervous system (hence the frequent instances of flushing of the skin) and is perceived as a threat/stimulus by the entire immune system, which springs into action and thereby contributes to destroying bacteria or virus.

It is well known that bacteria and viruses are more vulnerable to Biophotonic emissions than are somatic cells. BT forms pyrimidine dimers and otherwise disrupts the DNA of microorganisms. In contrast, as long as somatic cells are not metabolically active, they have the capability of withstanding modest amounts of biophotons emitted by blood cells.

Knott and other early researchers noted that BT has a complex effect on the immune system. On the one hand, BT stimulates the activity of white blood cells; on the other, excess amounts destroy various white blood cells. The first effect is the basis of the immune response explanation of the beneficial effects of BT. The second suggests a reason why BT seems so effective against Viral and Bacterial Infections and Autoimmune diseases. In autoimmune disorders it appears that the metabolically active T -cells and other immune cells absorb much greater numbers of biophotons than ordinary body cells, and this destroys them, thus slowing down or stopping the disease.

Activated T-cells in particular are prone to absorb secondary biophotons following BT as a source of energy just as they absorb, at a very high rate, glucose and other energy-bearing molecules. In effect, they are tricked by evolution.• Having specialized for hundreds of millions of years within the controlled environment of the bodies of animals in the art of absorbing as much endogenous biochemical energy as possible (via the "glucose shunt" a cell can absorb over 1,000 molecules of glucose per second) to achieve the high levels of activation needed to orchestrate and drive the powerful response of cellular immunity, they are not equipped to switch to shutting out excessive energy that is triggered from outside the body.

Source: Israeli Center for Energetics, Ltd.


Overall Assessment

In summary, Biophotonic Therapy operates in a somewhat complex manner but frequently with a surprisingly simple specificity and consequent virtual lack of side effects. In infectious diseases, the immunostimulatory effect and the induced secondary biophotons work in tandem. In autoimmune disorders, the concentrated secondary biophotons appear to be the main mode by which BT obtains its effects, suggesting that even in infectious diseases they play a much more important role than the immunostimulatory effect. The hypothesis that the “focused induced secondary emissions of biophotons are the most important mechanism of action of BT ” fits perfectly the pattern of damage that unusually high doses of BT can do as well as the known pattern of specificity of antimetabolite drugs (e.g., 2-CdAlCladribine) that resemble BT in the sense that they mimic energy-bearing molecules. BT can be viewed as the single most powerful of the antimetabolites.

The method of action of the energy-bearing secondary emissions from BT appears to lend it higher specificity than many chemotherapies aimed at the same applications, since to attain their effects such chemotherapies must deviate from the ideal purity of energy-bearing molecules such as glucose and ATP (Dillon (1994), pp .' 37-45). This suggests in turn that the negligible observed side effects of properly administered BT treatments are not the tip of an iceberg of hidden damage but rather that BT indeed has exactly the exceptionally high specificity that the above energy-bearing model implies. In other words, Biophotonic Therapy is not only safe; it is safer than competing chemotherapies. The dramatic advances over the past 50 years in medical science's understanding of physiology and in its ability to monitor disease states mean that it will now be possible to achieve a better grasp of how BT works. In turn, this will provide insight into various physiological processes as well as an opportunity to fine-tune the therapy and apply it to new indications, thus achieving significantly better results than the pioneers of BT from 1920 to 1996

Source: Israeli Center for Energetics, Ltd.


Clinical Studies

Biophotonic Therapy raises the resistance of the host and is therefore able to control many disease processes. A fundamental effect of BT is to "energize" the biochemical and physiological defenses of the body by the introduction of ultraviolet energy into the bloodstream that may, in part, be effective by producing small amounts of ozone from the oxygen circulating in the blood. The efficacy of this method is attested to by the remarkable and consistent recovery of patients with a wide variety of diseases, apparently unrelated etiologically. In addition, it may be stated that BT has never caused any adverse side effects nor has it ever worsened any disease in any patient, regardless of age group, race or sex and regardless of the number of treatments administered. Furthermore, there have not been any complications related to BT during long-term follow-up. In an infectious disease study, an average of 3.28 treatments per patient was administered. Laboratory studies were employed to confirm clinical improvement which occurred on an average of 19.2 days after institution of Biophotonic Therapy treatments. Sixty percent of the patients were considered clinically recovered and able to return to their occupation in two weeks or less.

The older Biophotonic Therapy units have been updated and are now available and FDA certified for use in the U.S. These units are being further evaluated for improvements; this is being carried out under a CRADA (Cooperative Research and Development Agreement) with the Lawrence Livermore National Laboratories of Berkeley, California. Steps are now being taken to arrange research protocols at several major Universities medical research centers on both the East and West coasts of the U.S. Focus will be on treatment of HIV, hepatitis, malaria, and those viruses immune to current antibiotics.

Source: Foundation for Blood Irradiation

 

 

UBIMEDICAL

DISCLAIMER: THE INFORMATION PROVIDED HEREIN IS NOT INTENDED AS A “PRESCRIPTION” FOR TREATMENT, NOR IS IT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE. UBI TECHNOLOGIES AND ITS AFFILIATES MAKE NO REPRESENTATION CONCERNING THE EFFICACY, APPROPRIATENESS, OR SUITABILITY OF ANY PRODUCTS OR TREATMENTS. THE INFORMATION CONTAINED HEREIN IS FOR EDUCATIONAL PURPOSES ONLY AND THE STATEMENTS HAVE NOT BEEN EVALUATED BY THE US FOOD AND DRUG ADMINISTRATION. THE ENTIRE RISK AS TO THE USE OF THIS INFORMATION IS ASSUMED BY USER.

 

 

 
 

Copyright © 2010-2011  UBI TECHNOLOGIES - UBIMEDICAL.COM   All Rights Reserved.